Abstract

BackgroundParoxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening terminal-complement-mediated disease resulting in intravascular hemolysis and thrombosis with significant morbidity and premature mortality. There exists no disease-specific quality-of-life (QOL) measure for PNH. Its QOL effects resemble those of hematologic cancers, which supports the use of cancer-specific QOL measures in PNH clinical trials. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 has published norms for many European and North American countries, but not for Asian countries. We investigated differences by Asian ethnicity in scores and item function on the EORTC QLQ-C30.MethodsThis secondary analysis focused on two non-inferiority PNH trials (301 and 302) comparing eculizumab and ravulizumab (n = 441). Analysis of covariance examined the main effect of Asian ethnicity on baseline EORTC QLQ-C30 scores, after adjusting for propensity scores encompassing trial, demographic and clinical factors. Mixed modeling of longitudinal data compared subscale scores in Asian vs. non-Asian patients, after propensity adjustment. Differential item function (DIF) was examined using ordinal regression models at baseline and longitudinally, to predict item score from total score, ethnicity, and their interaction to test for uniform DIF (significant main effect for Asian) and non-uniform DIF (significant Asian-by-total-score interaction).ResultsOf the 15 baseline domains, Asian patients scored slightly better on role and emotional functioning and slightly worse on constipation and diarrhea (0.22 < Cohen’s d < 0.36). In longitudinal models, Asians reported slightly higher appetite loss, diarrhea, and financial difficulties than non-Asians (R2 increment < 0.0005). There was negligible uniform and non-uniform DIF, i.e., R2 0 to 0.018, far below Zumbo’s (1999) criterion of 0.13. On average there were larger differences from norms for Asians (mean = 0.05, sd = 0.44) than non-Asians (mean = -0.07, sd = 0.36), but the size and direction of the differences varied considerably by domain, age, and gender.ConclusionWhen compared to norms, Asian patients showed no systematic biases. DIF results supported this finding. We conclude that Asian ethnicity does not impact interpretation of EORTC QLQ-C30 scores.

Highlights

  • The use of patient-reported outcomes (PRO) has amplified the patient’s voice in clinical research [1]

  • Trial 302 (ALXN1210-Paroxysmal nocturnal hemoglobinuria (PNH)-302) was conducted in PNH patients who were stable on eculizumab for at least six months and of whom half were randomized to switch to ravulizumab and the other half remained on eculizumab [26]

  • About one quarter of the Asians in the study were from Japan, 64% were from other parts of Asia or the Pacific (i.e., Australia, Korea, Malaysia, Singapore, Taiwan, Thailand, and Turkey), and just 9% total were from Europe, North America or Latin America

Read more

Summary

Introduction

The use of patient-reported outcomes (PRO) has amplified the patient’s voice in clinical research [1]. With the growth in the field of quality-of-life (QOL) research over the past three decades, there are often many options for measuring PROs for relatively common conditions. While it is possible to craft measures using items from selected domains developed by the prominent Patient-Reported Outcome Measurement and Information System (PROMIS) [3] and the NeuroQOL systems [4], these systems may lack the language translations needed for international clinical trials, and translation requirements can be arduous and demanding. There exists no disease-specific quality-of-life (QOL) measure for PNH. Its QOL effects resemble those of hematologic cancers, which supports the use of cancer-specific QOL measures in PNH clinical trials. We investigated differences by Asian ethnicity in scores and item function on the EORTC QLQ-C30

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call